FDA Approves Elzonris (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy

 FDA Approves Elzonris (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy

FDA Approves Elzonris (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy

Shots:
  • The approval is based on the STML-401-0114 (NCT 02113982) study assessing immunophenotypic diagnostic CD123, CD4 & CD56 patients in treatment-naïve and previously-treated patients IV
  • STML-401-0114 results: Elzonris(12 mcg/kg/day): ORR 90% (26/29); CR/CRc 72% (21/29); 45% of patients went for SCT post Elzonris treatment
  • Elzonris is a CD123-targeted therapy indicate to treat adult and pediatric patients with both treatment-naïve and previously-treated BPDCN and has also received FDA’s BTD and ODD with its BLA
    under review by the US FDA

Click here to read full press release/ article | Ref: PRNewsWire | Image: Pharma Journalist

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post